arbacicept

Arbacicept is a recombinant fusion protein developed by the Second Affiliated Hospital of Harbin Medical University for the treatment of neovascular age-related macular degeneration (nAMD). It is a biosimilar candidate of aflibercept, acting as a soluble decoy receptor (also known as a VEGF trap). The molecule consists of the extracellular domains of human vascular endothelial growth factor receptors 1 (VEGFR1) and 2 (VEGFR2) fused to the Fc portion of human IgG1. By binding to vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), and placental growth factor (PlGF) with high affinity, arbacicept prevents these ligands from binding to their native receptors on vascular endothelial cells. This inhibition suppresses pathological angiogenesis and reduces vascular permeability in the retina, which are the hallmarks of nAMD. The drug is typically administered via intravitreal injection and is currently in early-stage clinical development in China.

Other names

阿柏西普aflibercept biosimilar